Arthrex will make IPRs more expensive and uncertain, and the USPTO Director more powerful
The Supreme Court’s keenly-anticipated decision takes the review process even further away from the reasons for its establishment as a relatively quick and cheap way to challenge bad patents
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.